NIH Earmarks $3.5M for Lewy Body Dementia Biomarker Studies | GenomeWeb

NEW YORK (GenomeWeb) – The National Institutes of Health announced that it will commit $3.5 million to fund research identifying and developing biomarkers for Lewy body dementias (LBDs).

LBDs comprise two related neurodegenerative disorders characterized by the abnormal accumulation of alpha-synuclein in the brain — dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). The conditions primarily differ in the timing of the onset of cognitive and movement symptoms. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.